(Q62078702)

English

Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention

scientific article published on 4 January 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17205057%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17205057%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

acute promyelocytic leukemia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17205057%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17205057%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17205057%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

author name string

J Esteve

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17205057%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

L Escoda

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17205057%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

G Martín

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17205057%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

V Rubio

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17205057%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

J Díaz-Mediavilla

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17205057%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

M González

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17205057%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

C Rivas

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17205057%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

C Alvarez

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17205057%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

J D González San Miguel

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17205057%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

S Brunet

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17205057%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

J F Tomás

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17205057%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

M J Sayas

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17205057%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

P Sánchez Godoy

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17205057%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

P Bolufer

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17205057%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

Spanish Cooperative Group PETHEMA

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17205057%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

publication date

4 January 2007

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17205057%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17205057%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17205057%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17205057%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

446-452

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17205057%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404501

0 references

Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404501

7 January 2021

based on heuristic

inferred from DOI database lookup

All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404501

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404501

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404501

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment options for relapsed acute promyelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404501

7 January 2021

based on heuristic

inferred from DOI database lookup

Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404501

7 January 2021

based on heuristic

inferred from DOI database lookup

United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404501

7 January 2021

based on heuristic

inferred from DOI database lookup

Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404501

7 January 2021

based on heuristic

inferred from DOI database lookup

Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404501

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404501

7 January 2021

based on heuristic

inferred from DOI database lookup

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404501

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404501

7 January 2021

based on heuristic

inferred from DOI database lookup

Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404501

7 January 2021

based on heuristic

inferred from DOI database lookup

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404501

7 January 2021

based on heuristic

inferred from DOI database lookup

Curative chemotherapy for acute myeloid leukemia: the development of high-dose ara-C from the laboratory to bedside

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404501

7 January 2021

based on heuristic

inferred from DOI database lookup

Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404501

7 January 2021

based on heuristic

inferred from DOI database lookup

Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404501

7 January 2021

based on heuristic

inferred from DOI database lookup

Retinoic acid resistance in acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404501

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404501

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404501

7 January 2021

based on heuristic

inferred from DOI database lookup

Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404501

7 January 2021

based on heuristic

inferred from DOI database lookup

Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404501

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404501

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q62078702&oldid=1584613209"